Compare Immunovant Inc. Common Stock (IMVT) vs Marvell Technology Inc (MRVL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Immunovant Inc. Common Stock vs Marvell Technology Inc — how do they compare? Immunovant Inc. Common Stock trades at $30.47 (market cap $6.25B), while Marvell Technology Inc trades at $275.28 (market cap $246.84B). The key difference: Marvell Technology Inc is far larger — about 39.5× Immunovant Inc. Common Stock's market cap, and Marvell Technology Inc pays a 0.09% dividend while Immunovant Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Immunovant Inc. Common Stock for 1 Days and Marvell Technology Inc for 42 Days on average.
| IMVT | MRVL | |
|---|---|---|
Market Cap | $6.25B | $246.84B |
Volume | 1,755,411 | 29,003,830 |
Sector | Health | Technology |
52-Week High | $44.96 | $316.43 |
52-Week Low | $17.03 | $73.73 |
Typical Hold Time | 1 Days | 42 Days |
Enterprise Value | $5.35B | $248.19B |
Dividend Yield | — | 0.09% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
Marvell Technology (MRVL) trades at $274.66, down 3.52% on the day but maintains strong technical momentum with bullish moving averages and key support at $267. The company shows impressive earnings beats in recent quarters with Q2 2026 EPS of $0.94 beating expectations, while analyst consensus remains overwhelmingly bullish with 84% buy ratings. Recent news highlights Marvell's AI chip growth potential, including a major Google partnership and raised 2028 revenue guidance to $18 billion.
Marvell presents compelling growth prospects driven by AI infrastructure demand and custom chip expansion, though elevated valuation ratios (P/E 90.95, P/S 25.77) warrant caution. Key risks include execution challenges in scaling custom silicon business and competitive pressures in the semiconductor sector. The $327.86 consensus price target suggests 19% upside potential from current levels.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Immunovant Inc. Common Stock
Immunovant is a clinical-stage immunology company developing therapies for autoimmune diseases. Its pipeline includes anti-FcRn antibody candidates designed for subcutaneous administration.
Read more on IMVT →About Marvell Technology Inc
Marvell Technology is a leading fabless chipmaker focused on networking and storage applications. Marvell serves the data center, carrier, enterprise, automotive, and consumer end markets with processors, optical interconnections, application-specific integrated circuits (ASICs), and merchant silicon for Ethernet applications. The firm is an active acquirer, with five large acquisitions since 2017 helping it pivot out of legacy consumer applications to focus on the cloud and 5G markets.
Read more on MRVL →
